Navigation Links
Vion Reports 2008 Third Quarter and Nine-Month Results
Date:11/3/2008

vo poor-risk acute myelogenous leukemia. Clinical trials of laromustine (Cloretazine(R), VNP40101M) with cytarabine in elderly patients with acute myelogenous leukemia, with temozolomide in brain tumors, and with stem cell transplantation in advanced hematologic malignancies, are also being conducted. Triapine(R), a potent inhibitor of a key step in DNA synthesis, is being evaluated in clinical trials sponsored by the National Cancer Institute. For additional information on Vion and its product development programs, visit the Company's Internet web site at http://www.vionpharm.com.

This news release contains forward-looking statements. Such statements are subject to certain risk factors which may cause Vion's plans to differ or results to vary from those expected, including Vion's potential inability to file a New Drug Application or obtain regulatory approval for its products, particularly laromustine (Cloretazine,VNP40101M), delays in the regulatory approval process or delays or unfavorable results of drug trials, the possibility that favorable results of earlier preclinical studies, clinical trials or interim clinical trial data are not predictive of safety and efficacy results in later or final clinical trials, the need for additional research and testing, the inability to manufacture product, the potential inability to secure external sources of funding to continue operations, the inability to access capital and funding on favorable terms, continued operating losses and the inability to continue operations as a result, and a variety of other risks set forth from time to time in Vion's filings with the Securities and Exchange Commission, including but not limited to the risks attendant to the forward-looking statements included under Item 1A, "Risk Factors" in Vion's Form 10-K for the year ended December 31, 2007 and Form 10-Q for the quarter ended June 30, 2008. In particular, there can be no assurance
'/>"/>

SOURCE Vion Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. AMICAS Reports Financial Results for the Third Quarter Ended September 30, 2008
2. Neovasc Reports Development Progress, Streamlined Operations and Issuance of Options
3. NxStage Reports Third Quarter 2008 Financial Results
4. Study reports Double Balloon Endoscopy useful for diagnosis and treatment of obscure GI bleeding
5. The Ensign Group, Inc. Reports Third Quarter 2008 Earnings; Reaffirms 2008 Guidance
6. Gen-Probe Reports Strong Financial Results for Third Quarter 2008, Raises Full-Year EPS Guidance
7. Poniard Pharmaceuticals Reports Third Quarter 2008 Financial Results and Corporate Update
8. Nuvelo Reports Third Quarter 2008 Financial Results
9. Claimsnet.com Reports Third Quarter 2008 Results
10. Remuda Ranch Reports Many Individuals With Eating Disorders Are Not Getting Help They Need
11. Palomar Medical Reports Financial Results for Third Quarter 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/26/2014)... July 26, 2014 The report “Gourmet ... Himalayan Salt, Flake Salt, Specialty Salt), Application (Bakery & ... Savory) & Geography - Global Trend & Forecast to ... analyses and projection of the market size in terms ... and restraining factors for the gourmet salts market, with ...
(Date:7/26/2014)... (PRWEB) July 26, 2014 The European gas ... Europe with analysis and forecast of revenue. The gas chromatography ... in 2013, and is estimated to grow to around $445.5 ... 2013 to 2018. , Browse through the TOC of the ... the in-depth analysis provided. This report also provides a glimpse ...
(Date:7/26/2014)... “Today, we introduce our new items of ... the world. All these models are offered at discounted ... UK market,” says the CEO of the company. DressesOnlineShops.co.uk ... special occasion outfits. , Ladies have to find a ... one of the best choices for many ladies worldwide ...
(Date:7/26/2014)... 26, 2014 According to ... by Vkool.com, this is a comprehensive guide ... for treating all types of disorders ...     Tinnitus due to Ménière's disease , ...     Nerve pathway tinnitus ,     Inner, middle ...
(Date:7/26/2014)... ON (PRWEB) July 26, 2014 Studio B ... type of implant, often called Teeth in a Day, gives ... with a full set of bright, pearly whites with very ... teeth are permanent, look and feel just like natural teeth, ... and regular checkups. Studio B Dental is one of ...
Breaking Medicine News(10 mins):Health News:Gourmet Salts Market Worth $1,340.9 Million by 2019 - Report by MarketsandMarkets 2Health News:Gourmet Salts Market Worth $1,340.9 Million by 2019 - Report by MarketsandMarkets 3Health News:Gourmet Salts Market Worth $1,340.9 Million by 2019 - Report by MarketsandMarkets 4Health News:Europe Gas Chromatography Reagents Market is Expected to Reach $445.5 million in 2018 - New Report by MicroMarket Monitor 2Health News:Europe Gas Chromatography Reagents Market is Expected to Reach $445.5 million in 2018 - New Report by MicroMarket Monitor 3Health News:Europe Gas Chromatography Reagents Market is Expected to Reach $445.5 million in 2018 - New Report by MicroMarket Monitor 4Health News:Europe Gas Chromatography Reagents Market is Expected to Reach $445.5 million in 2018 - New Report by MicroMarket Monitor 5Health News:Famous Supplier DressesOnlineShops.co.uk Announces Its New Selection of Prom Dresses for the UK Market 2Health News:Tinnitus Miracle Book Review Exposes Thomas Coleman's Guide for Treating Tinnitus – Vkool.com 2Health News:Studio B Dental Improves Patient Smiles with All-on-Four Dental Implants 2
... of the latest fleet golf car and the role ... a leader in,manufacturing execution systems (MES) for the integrated ... event,titled "Launching the E-Z-GO Fleet Golf Car: Integrating Manufacturing,Execution ... place on Thursday, March 6, 2008 at 2:00 p.m. ...
... accuracy with Microsoft Dynamics ... ... AliMed, a producer and catalog-based distributor of medical,products, has chosen Microsoft ... business and expanding its interaction with,customers. The technology will enable AliMed ...
... DENVER, March 4 Global Med Technologies(R),Inc. ... GLOB), an,international e-Health, medical information technology company, will ... Monday, March 10, 2008, before,the market open. The ... p.m. EDT,on the same day., (Logo: ...
... or tablets avoid the pain and side effects of shots, ... allergy immunotherapy -- in the form of drops or tablets ... for asthma medications in children who have what,s known as ... hopes that these oral medications might someday replace injections, never ...
... March 4 The number of Arab,Americans is ... second largest,concentration of people of Arab descent outside ... grows, so do their healthcare needs. Like many,other ... and educational challenges in accessing health information and,care., ...
... Patient Citizens Promotes National Kidney Month Programs to,Combat ... Nationwide -, WASHINGTON, March 4 DaVita ... comprised of more than 22,000,dialysis and pre-dialysis patients ... life for all dialysis patients through education and,advocacy ...
Cached Medicine News:Health News:E-Z-GO and Visiprise to Participate in New Product Introduction Event with IndustryWeek 2Health News:E-Z-GO and Visiprise to Participate in New Product Introduction Event with IndustryWeek 3Health News:Medical Products Distributor Gains New Flexibility With Its Selection of Microsoft Dynamics AX and Microsoft Dynamics CRM 2Health News:Medical Products Distributor Gains New Flexibility With Its Selection of Microsoft Dynamics AX and Microsoft Dynamics CRM 3Health News:Medical Products Distributor Gains New Flexibility With Its Selection of Microsoft Dynamics AX and Microsoft Dynamics CRM 4Health News:Medical Products Distributor Gains New Flexibility With Its Selection of Microsoft Dynamics AX and Microsoft Dynamics CRM 5Health News:Global Med Technologies(R), Inc. to Announce Fourth Quarter and Year End Results on Monday, March 10, 2008 2Health News:Global Med Technologies(R), Inc. to Announce Fourth Quarter and Year End Results on Monday, March 10, 2008 3Health News:Oral Allergy Immunotherapy Helps Control Asthma 2Health News:Oral Allergy Immunotherapy Helps Control Asthma 3Health News:International and Domestic Leaders to Convene to Tackle Health Issues in the Arab American Community 2Health News:Kidney Patient Advocacy Community Joins National Effort to Raise Awareness about Health Crisis Impacting more than 26 Million Americans 2
(Date:7/24/2014)... , July 24, 2014  Restore Health, a ... compounded pharmaceuticals, announced that it is now offering ... to each individual based upon their particular genetic ... understanding the interaction between a patient,s genetics and ... very excited to provide this new service to ...
(Date:7/24/2014)... 24, 2014  Abaxis, Inc. (NasdaqGS: ABAX ... systems, today reported financial results for the first fiscal ... overview: , Revenues of $47.5 million, up 10% ... of $0.21, up 50% over last year,s comparable quarter. ... of $7.2 million, up 20% over last year,s comparable ...
(Date:7/24/2014)... 24, 2014 Omnicell, Inc. (NASDAQ: ... and supply management solutions and analytics software for ... 31, to discuss the Company,s Second Quarter 2014 ... 2014 earnings conference call and webcastWhen: , ... Lipps, chairman, president and chief executive officer ...
Breaking Medicine Technology:Restore Health Launches Pharmacogenetic Testing, Enhancing Its Suite of Personalized Medicine Goods and Services 2Restore Health Launches Pharmacogenetic Testing, Enhancing Its Suite of Personalized Medicine Goods and Services 3Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 2Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 3Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 4Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 5Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 6Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 7Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 8Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 9Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 10Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 11Omnicell to Release Second Quarter 2014 Earnings Results on July 31 2
... Food and Drug Administration (FDA) says children and pets should not come in contact with ... menopause. , , , ... , , ... , The agency also wants ...
... AUSTIN, Texas ,  July 29 Vermillion, Inc. (Nasdaq: VRML ), a molecular diagnostics ... issuance of Q2 financial results on Monday, August 16, 2010 . , ... Conference Call Information , , ... live conference call via phone, dial (800) 757 8521 from the United States ...
Cached Medicine Technology:FDA CONSUMER HEALTH INFORMATION - Keep Kids, Pets Away From Skin Sprayed With Evamist 2Vermillion to Host Conference Call and Web Cast to Present Company Update and Review Financial Results for the Second Quarter 2010 2Vermillion to Host Conference Call and Web Cast to Present Company Update and Review Financial Results for the Second Quarter 2010 3
Straight chisel for scoring, cutting, scraping, cleaning and sculpting bone....
Custom-made chisels....
Lewin Bone Forceps, serrated and slightly curved. To hold, stabilize, rotate, reduce and,compress bone....
To elevate, dissect, scrape and apply traction to bone and soft tissue....
Medicine Products: